Skip to content

EV / sales at other companies

Indivior Pharmaceuticals, Inc.
 logo
Indivior Pharmaceuticals, Inc. INDV
3.1×+2.1×
Catalyst Pharmaceutical logo
Catalyst PharmaceuticalCPRX
3.8×-0.6×
Avanos Medical logo
Avanos MedicalAVNS
0.0×
Pacira BioSciences, Inc. logo
Pacira BioSciences, Inc.PCRX
1.6×-0.1×
Supernus Pharmaceuticals logo
Supernus PharmaceuticalsSUPN
3.6×+1.0×
Theravance Biopharma logo
Theravance BiopharmaTBPH
5.4×-0.5×

Other financials

Income statement

See full
Revenue$193.5M+8.9%
Gross profit$117.2M+20.5%
Operating income$30.9M+42.5%
Net income$14.5M+500%
EPS (diluted)$0.40+471%

Balance sheet

See full
Cash & equivalents$289.6M+147%
Total debt$5.2M-19.5%
Total equity$312.4M+33.3%
Total assets$1.7B+1.3%

Cash flow

See full
Operating cash flow$57.1M+3.1%
CapEx$270.0K-66.2%
Free cash flow$56.8M+4.1%

Valuation

See full
Market cap$1.15B+20.4%
Enterprise value$869.67M+2.5%
P/E15.4×-6.4×
P/S1.5×0.0×

Profitability

See full
Gross margin60.7%+3.0pp
Operating margin23.7%+2.3pp
Net margin9.4%+2.8pp
FCF margin41.4%+10.4pp

Returns & leverage

See full
Return on equity27.4%+8.2pp
Debt / equity0.0×
Current ratio1.7×+0.6×

Where this comes from

Calculated from Collegium Pharmaceutical, Inc.’s reported figures.

Based on the most recent quarter.

The official record: Collegium Pharmaceutical, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Collegium Pharmaceutical, Inc.'s ev / sales.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Collegium Pharmaceutical, Inc.'s EV / sales?
Collegium Pharmaceutical, Inc. (COLL) reported EV / sales of 1× in Q1 2026.
How has Collegium Pharmaceutical, Inc.'s EV / sales changed year-over-year?
Collegium Pharmaceutical, Inc.'s EV / sales decreased by 24.7% year-over-year, from 1.3× to 1×.
What is the long-term trend for Collegium Pharmaceutical, Inc.'s EV / sales?
Over 5 years (2020 to 2025), Collegium Pharmaceutical, Inc.'s EV / sales has grown at a -1.7% compound annual growth rate (CAGR), from 1.7× to 1.6×.
What does EV / sales mean?
Enterprise value at the quarter end divided by trailing-twelve-month revenue. A capital-structure-neutral revenue multiple, useful when earnings are negative.